Nearly fifteen percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy.
However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.
Chemotherapies work primarily by mediating B-cell lymphoma 2 (Bcl-2) family proteins, which are responsible for regulating cell death. Depending on their function, ...
Nearly fifteen percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy.
However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.
Chemotherapies work primarily by mediating B-cell lymphoma 2 (Bcl-2) family proteins, which are responsible for regulating cell death. Depending on their function, ...